Metropolis Healthcare Limited (METROPOLIS) Earnings Call Transcript
August 5, 2026
Earnings Call Speaker Segments
Good day, everyone, and welcome to Metropolis Healthcare's Q1 FY 2027 earnings conference call, brought to you by JM Financial Institutional Securities. This call might include forward-looking statements regarding the company, based on its beliefs, opinions and expectations as of today's date. Such statements are not a guarantee of future performance and could involve risks and uncertainties that are hard to predict. As a reminder, every participant line will be in listen-only mode, and you'll have a chance to ask questions once the presentation ends. If you require assistance at any point during this call, please signal an operator by pressing star then zero on your touchtone phone. Kindly note that this conference is being recorded. I'll now turn the conference over to Mr. Abin Benny from JM Financial Institutional Securities. Thank you, and over to you, sir.
Thanks, Albert. Good morning, and a warm welcome to everyone joining the Metropolis Healthcare Q1 FY 2027 earnings call, which JM Financial is hosting. With us on today's call are the management team: Ms. Ameera Shah, Promoter and Chairperson; Mr. Surendran Chemmenkotil, Managing Director; Mr. Sameer Patel, Chief Financial Officer; and Mr. Mohan Menon, the Chief Marketing Officer. I'll now turn the call over to Ms. Ameera Shah for her opening remarks. Thank you, and over to you, ma'am.
Hello, and good morning to all of you. Thanks for being with us on this call, which covers Q1 FY 2027 results for Metropolis Healthcare. With me are Surendran, our MD; Sameer Patel, CFO; Mohan Menon, CMO; the remainder of our leadership group; and SGR Investor Relations Partner. The investor presentations are now available on the exchanges and on our website, and I trust you've had a chance to review them. Before turning to company-specific updates, here's a quick view of the wider backdrop: India's diagnostics sector has entered a period of durable structural expansion, driven by 3 mutually reinforcing shifts. First, patients, clinicians and institutions are gravitating toward organized, quality-focused diagnostic providers, as expectations keep climbing around accuracy, consistency, advanced testing capabilities and service standards. That is speeding the move away from non-standardized, unorganized diagnostics and opening an opportunity for trusted branded players that have scale and quality. Second, India's healthcare ecosystem is growing past metropolitan markets. Additional hospital capacity, higher OPD and IPD volumes, more specialists being available, and better access in Tier 2 and Tier 3 cities are drawing more patients into the formal healthcare system. Hospitals and institutional partners are likewise outsourcing a bigger portion of specialized and high-end testing to providers that have strong quality systems, comprehensive test menus, scientific depth and nationwide reach.
Third, the ways patients are treated keep getting more sophisticated. Pharma's increased emphasis on targeted therapies, biologics, and biosimilars in oncology, neurology, and autoimmune disorders is driving greater demand for accurate diagnosis, patient stratification, treatment selection guided by biomarkers, and continuous monitoring. That is widening the part played by molecular, genomic, and immunological testing throughout the patient journey. Taken together, these developments are enlarging the diagnostics market we can serve and generating a substantial structural opening in specialty testing. That opening won't be distributed uniformly across the industry. Specialty diagnostics is an appealing segment, yet it is no guaranteed easy win. You can't achieve success merely by introducing additional tests or putting money into sophisticated instruments. It demands years of commitment to scientific know-how, quality systems, clinical credibility, relationships with specialists, and a wide portfolio of high-end tests. Such capabilities erect significant barriers to entry and set apart providers able to compete in this market over the long term. Metropolis has developed these capabilities across many decades. Our Specialty portfolio covers over 2,200 tests spanning gastroenterology, nephrology, neurology, oncology, and chronic disease categories, among them allergy and autoimmunity. This range lets us underpin specialist-led pathways spanning diagnosis, treatment selection, and continuous monitoring. We also introduced 36 new tests in the quarter, on top of 347 additions in FY 2026, which included integrating the core test menu, further reinforcing our capabilities in high-growth, high-value specialty categories.
A 99% EQAS score—that's External Quality Assessment Score—along with 99.99% report accuracy and a lab network where each lab is accredited or benchmarked against recognized quality standards: all of this underpins our scientific differentiation. Roughly 30,000 specialist doctors nationwide order tests via Metropolis, as does every leading hospital, whether individual or chain, in the country—a reflection of how deeply clinicians trust us, trust earned over many years via scientific programs, educational initiatives, sustained engagement, and a thoroughly science-driven operational culture at Metropolis, which stewards the confidence built up over the years. Turning to tech and digital transformation, technology continues to be a strategic pillar of our long-term growth. We are carrying out a company-wide automation and digital transformation program that spans labs, customer engagement, vendor consolidation, commercial operations, finance, procurement, and support functions. Through these efforts, we are bolstering data governance and making sure patient data is handled in a DPDP-compliant way, with a sharp focus on privacy, security, and responsible use of information. Inside labs, automation and in-platform standardization are lifting quality, throughput, and turnaround times, especially in oncology and specialty diagnostics. Outside the laboratories, AI and automation are boosting workflow efficiency, reinforcing decision-making, elevating customer engagement, bettering inventory management, and streamlining back office operations. All together, these efforts are delivering meaningful productivity gains and building an operating model that is more scalable, data-led, and efficient throughout the organization.
That expansion remains rooted in quality — robust scores from external quality assurance, a high level of report accuracy, and a lab network that runs to accreditation and benchmarking standards. Now looking at the quarter we're in, Q1 FY 2027, we got off to a solid start. We saw healthy growth in patient volumes as well as test volumes, and that fed through to financial performance that was even stronger. We beat the guidance we had stated, with revenue up roughly 17% year-on-year, largely on the back of volume growth, and margins widened thanks to operating leverage and ongoing efficiency gains. The robust rise in patient volumes comes from a mix of structural industry trends and focused execution. We keep building out our presence in Tier 2 and Tier 3 markets, where awareness of high-quality diagnostics is climbing at the same time as healthcare access improves. We see this as a good beginning to our year, and we believe we can hold to a revenue growth outlook of 14%-16% for the year, which we expect will come mainly from volume growth. On margins, with continued operational efficiencies and cost optimization initiatives supporting us, we anticipate an improvement of 100 basis points-150 basis points on EBITDA in the current financial year. Across this year and the next, our focus stays on reaching an EBITDA margin of 27%-28%.
Turning to inorganic growth, the other acquisitions we made recently have been completely integrated by now and are delivering results as we expected. Those businesses are gaining from Metropolis's broader network, its operating processes, and its commercial capabilities. At Core Diagnostics, integration is in its last phase. Given that 1 year has passed since we acquired the company, this is a good moment to look back at what we set out to achieve with the deal and how far we have come. The first objective we had was to create a robust genomics platform for Metropolis. When we weighed building versus buying in genomics, we understood that although buying sequencing platforms and equipment is fairly easy, the true gestation period in genomics comes from developing scientific expertise, R&D capabilities, and the capacity to interpret complex genomic data accurately. We felt that buying Core Diagnostics would speed up our genomics journey by 2 to 3 years, and that has turned out to be the correct call. Across the past year, our genomics portfolio has grown twofold and now ranks among the fastest-growing segments in our Specialty business. Our second goal in acquiring Core was to make our brand stronger in North India by building deep relationships with clinicians and hospitals. We aimed to draw on Core Diagnostics' solid ties with top hospitals and doctors.
During the last 12 months, with support from our genomics and specialty portfolio, we've considerably reinforced our scientific engagement across the region. Consequently, North India is now responsible for 18% of company revenue — previously a single digit share prior to the acquisition — and has become the fastest-growing region within our network. Goal number three involved generating shareholder value by means of disciplined acquisitions. We bought a distressed, loss-making business, Core, at an appealing valuation below 2x revenue, together with a clear roadmap for turning it into an operation able to deliver EBITDA margins near 25% within three to four years of acquisition. Using the EBITDA Core Diagnostics is projected to produce in FY 2027 — merely the second year as part of Metropolis — our effective acquisition multiple comes to roughly 10x EBITDA. That illustrates the value disciplined acquisitions plus successful integration can generate for shareholders. With Core integration moving forward, our attention is shifting progressively from integration toward growth. Encouraging early signals are visible as we leverage Metropolis' pan-India network to broaden the reach of Core super specialty capabilities, pushing higher test volumes, enhancing network utilization, and generating operating leverage. This additionally reinforces our specialty diagnostics portfolio along with our capacity to serve clinicians and patients using advanced testing solutions.
We feel confident that at Core we can boost both revenue and EBITDA growth moving forward, in line with the estimates we gave earlier. As we progress into FY 2027 under the Metropolis 3.0 strategy, our attention will be channeled into five main execution priorities. First is speeding up network expansion. We will keep growing our network to make access easier, particularly in Tier 2 and Tier 3 towns, and push higher sample volumes through the laboratories we recently commissioned, which will lead to better capacity utilization, operating leverage, and profitable growth. Our target is to open roughly 400 centers-500 centers in Tier 2 and Tier 3 towns during this year. Second is making specialty diagnostics stronger. We will keep broadening our advanced testing portfolio while engaging more deeply with clinicians. Growth in specialty diagnostics also lifts higher routine and allied test volumes, which improves volume share and customer retention. Our goal is to raise this portfolio's contribution to 45% from the current 40%. Third, we will reinforce our TruHealth portfolio through targeted wellness offerings and greater customer engagement, which drives higher adoption, customer lifetime value, and market share in preventive diagnostics. We have taken TruHealth past pathology to include basic radiology, vital checks, and consultations. We will keep adding to the number of our centers so that all these services are available under one roof.
It might not turn into a massive revenue driver, but it definitely helps lift average revenue per patient and deepen engagement with our consumers. Number four is about using technology and AI. We'll keep investing in digital platforms, automation, and AI, which will enhance customer experience, lab efficiency, and both doctor and patient engagement, while supporting profitable growth over the long term. Five, we're pursuing disciplined inorganic growth. With our recent integrations going well, we're building out our acquisition funnel. We'll keep assessing high-quality assets that are strategically aligned and can create long-term value through our proven integration playbook. With that, I'll hand the call over to Suren, who will walk you through the business performance for Q1 FY 2027. Thank you. Suren, over to you.
Thank you, Ameera, and good morning to all of you. The first quarter of financial year 2027 represents a robust beginning to the year, with growth spread widely across our businesses, geographies, and channels. Revenue rose roughly 17% year-on-year to INR 450 crore, surpassing the guidance we had stated, and EBITDA margin widened by 210 basis points to 25.2%. Typically, the first quarter tends to be a weaker one for Metropolis. This year, though, revenue climbed about 6% on a sequential basis, which mirrors seasonal momentum, sound operating leverage, and disciplined execution. Growth was spread broadly across channels, geographies, and test categories. B2C advanced by 18%, while B2B rose by 15%. Every region posted double digit growth, and routine, semi-specialty, specialty, and TruHealth each also logged high-double digit growth in this quarter. What stands out as especially encouraging is that this performance came predominantly from volume. Even with no price increase across the last 18 months, we achieved 17% revenue growth, backed by 10% growth in patient volumes and 11% growth in test volumes, with the remainder driven by a richer mix and better realizations. This shows the strength of our underlying business and the structural demand drivers underpinning the diagnostic industry. As you are aware, the sole industry-wide price increase during this period applied to CGHS tests.
That gave other industry players a one-time benefit considerably larger than what it gave us. For our part, it represents a very small piece of the overall business. Growth in volume came from network expansion combined with better productivity throughout our existing network. Over the past 12 months, we added over 500 service centers, among them 300 centers in quarter one 2027, and we remain on track to add more than 500 centers during the current financial year. We now operate across 750 towns in the country and are deepening our presence in existing as well as new territories. Network expansion strategy remained a key growth enabler for us. Across the last two years, we have significantly strengthened our presence while simultaneously deepening our footprint within the existing markets. The expanding network is improving accessibility, driving patient acquisition, and increasing sample throughput across our laboratory infrastructure. Our center-to-laboratory ratio improved from 1:21 a year ago, to 1:21 in quarter one, and we remain on track to improve this to around 1:30 by year-end, creating meaningful operating leverage as utilization continues to improve. Importantly, our expansion strategy is data-driven rather than opportunistic. Every new center is selected based on detailed market mapping, including population density, healthcare infrastructure, competitive intensity, and our ability to establish a strong market position.
By taking this disciplined approach, we can reach underserved markets, reinforce our brand presence, and enhance access to quality diagnostics. In addition to expanding, we have boosted the productivity of our existing network via focused operating initiatives. We keep raising throughput at high-potential centers, rationalizing underperforming locations, and redeploying resources toward more productive markets. Volume growth this quarter came from a balanced mix of healthy growth across our mature centers and the ramp-up of centers added over the last 12 months. Ongoing investments in micro-marketing, deeper clinician engagement, expanded test menus, and the targeted activation of newly launched centers are speeding up growth across both existing and new markets. All of this together gives us confidence that our growth momentum is broad-based, structural, and sustainable. Turning to our sales channels, our B2C business posted 18% revenue growth, with a balanced contribution from enhanced revenue across mature centers and the ramp-up of centers added over the last year. Growth was strong across our own centers and across Tier 2 and Tier 3 markets, with rural centers delivering 36% revenue growth. CLM-led customer engagement, local micro-marketing, strong brand pull, and increasing digital adoption all contributed to patient acquisition. Specialty revenue within B2C grew by 21%, while TruHealth and value-added offerings such as body vital checks, consults, and ECG supported higher revenue per patient.
Our B2B business expanded 15%, driven by an intentional emphasis on hospitals, clinicians, and high-quality organized institutions. We're focusing on partnerships where scientific capabilities, Specialty portfolio, service quality, and a nationwide network give us a stronger right to win. Through our partner portal and other digital enablement efforts, it's becoming simpler for partners to engage with us, which improves visibility, service responsiveness, and access to our broader test menu. With a footprint spanning over 750 towns, we're also going after additional business from smaller laboratories and hospitals in those markets, which leaves us considerable headroom for growth. Our position in North India has been reinforced consistently. Revenue from that region rose 19% year on year and now accounts for 18% of our total revenue, backed by the successful integration of Core Diagnostics, Scientific Pathology in Agra, and DAPIC Dehradun. Our approach has long been to acquire high-quality assets in a given geography and then generate sustained organic growth by capitalizing on our strong brand, deepening doctor engagement, expanding our network, and strengthening our test portfolio. We stay confident about further growing revenues and market share from North over time. Metropolis is trusted by the best hospitals and leading specialists for their specialized testing needs.
We'll keep growing the B2C side in chosen pockets of the North India markets — Delhi, Punjab, and Uttar Pradesh plus nearby regions — but the bulk of our operation will still run on B2B markets, powered by our strength in specialty diagnostics and our strong ties with clinicians and hospitals. The acquisitions we made recently in Agra and Dehradun are doing very well too, and both businesses are tracking ahead on revenue growth and EBITDA. We stay confident about further lifting our revenue and market share in North India over time. Turning to specialty testing and TruHealth. Both of these strategic growth engines keep performing well. TruHealth revenues were up 22%, backed by integrated preventive healthcare offerings and targeted digital customer acquisition initiatives. Radiology integrated wellness packages rose by more than 40%, and premium TruHealth packages rose by more than 50%, led by doctor consultations, body vital checkups, and ECG-led extensions. Specialty diagnostics was up 17% during the quarter, backed by growing adoption of advanced testing, deeper clinician engagement, and cross-selling of Core Diagnostics, oncology and super specialty capabilities across the Metropolis network. Our genomics capabilities and the Core super specialty menu are increasingly complementary. Genomics brings advanced testing and interpretation capabilities, while Core adds a deeper super specialty oncology portfolio and established clinician relationships.
So at this point we're bringing the Core test menu out to our current customers, to prescribing clinicians and to service networks throughout India — widening access to those tests and growing our share of specialty testing. Core Diagnostics is in the last stage of integration, and our focus stays on speeding up specialty volumes by leveraging our nationwide reach and a broader clinician network. Our International business kept performing well, turning in healthy growth in both revenue and EBITDA. In 2 of the 5 countries where we operate, we hold market leadership, and we rank among the top three players in every one of those markets. The business model mirrors India's, with specialized testing offshored to our reference laboratories in India, but the operating environment across African markets differs considerably. Through the years, we've gained a deep understanding of these markets and developed the capabilities needed to succeed in them. We're still optimistic about how strong the brand we've built internationally is, and we're confident that we'll keep growing our business across these markets. Turning to margins and productivity: EBITDA margin widened to 25.2%, which is 210 basis points better year-on-year and ahead of the guidance we gave. That expansion came from healthy volume-led operating leverage, disciplined cost management, and ongoing progress on our productivity agenda.
One major driver has been our lab transformation initiative. Across the network we're standardizing the testing platform, consolidating vendors, boosting automation, and driving better procurement efficiencies. These efforts sit at varying stages of roll-out. The ones already in place are lifting throughput, turnaround time, material productivity, and lab utilization, and we expect additional gains as the remaining platform transitions and automation initiatives go live over the quarters ahead. Importantly, our organic business posted healthy margin expansion both year-on-year and sequentially. That came despite the relatively lower margin profile of Core Diagnostics and the effect of moving annual employee increments from July-April this year. Finally, over the past 12 to 18 months, we've strengthened the leadership team, finished integrating acquisitions, broadened our network, and substantially upgraded our operational capabilities. With strong momentum across all growth engines, a healthy volume-led growth trajectory, and multiple productivity initiatives starting to scale, we remain confident in delivering sustainable, profitable growth and in continuing to outperform the diagnostic industry over the medium term. With that, I'll hand it over to Sameer, who will take us through the financial highlights. Thank you, and over to you, Sameer.
Thanks, Suren. Morning, everyone. I'll take you quickly through the main financial highlights for quarter one of FY 2027. Revenue came in at INR 450 crore, up 17% year-on-year, helped by 10% growth in patient volume and 11% growth in test volume. B2C revenue for the quarter rose 18% year-on-year, while B2B grew 15% over the same basis. Our focused segments kept performing well. TruHealth accounted for 18% of quarter one FY 2027 revenue and grew 22% year-on-year. Specialty made up 40% of revenue and grew 17% year-on-year. Core Diagnostics was acquired in March 2025, so it was already in the base for Q1 FY 2027, whereas the DAPIC Dehradun and Scientific Pathology acquisitions in Agra closed near the end of Q1 FY 2027. As a result, the Q1 FY 2027 numbers are now consolidated. Turning to margins, Q1 EBITDA was INR 113 crore, up 27% year-on-year. EBITDA margin widened 210 basis points to 25.2%. Q1 PAT came to INR 57 crore, growing 26% year-on-year. PAT margin widened 90 basis points to 12.6%. With that, I'll open the floor for questions and answers.
Thanks. We're moving into the question-and-answer portion now. To ask a question, you can press star and one on your touchtone phone. Should you want out of the question queue, press star and two. We ask that participants use handsets when posing a question. Ladies and gentlemen, we'll hold for a moment as the queue comes together. Our first question is from Tausif Shaikh at BNP. Go ahead.
Morning, and thanks for having me — appreciate the chance to speak. Nice work on the solid set of numbers. My first question concerns the 10% patient volume growth in the quarter. Could you break that out for us between B2B and B2C for the quarter separately? And some color would help on the strong volume growth we saw this quarter, given it was a seasonally weak quarter and the monsoon came late?
When you look at patient volume, B2C is growing at roughly 13.5%, while B2B is up around 6%. So that's how the volume breaks down between B2B and B2C.
When you look at patient volume growth in Q1, I'd say it comes down to two factors. We also brought up a few of the elements that are pushing the industry forward more broadly. Clearly, one piece is execution — building access in markets where diagnostics wasn't often prescribed, and establishing market categories for tests where previously people weren't being diagnosed at all. Another piece is seasonal momentum. Q4 was a normal quarter, not an exceptionally strong one. We can't say for sure whether some overflow from that quarter carried over and made Q1 a bit stronger than it typically is. It's a little hard to fully dissect why, but we have a few theories about what might be behind it.
Thank you, that's useful. My next question, Ma'am, is about how you're approaching Tier 2 and Tier 3 cities, and how you compete with standalone labs. What I'd like to know is whether Metropolis is pursuing O&M agreements or regional lab management arrangements with standalone operators — situations where Metropolis takes over running those labs and begins building franchises, with ultimately some form of profit-sharing arrangement between the standalone labs and Metropolis?
So essentially, we already have this lab-on-lease business model. We've been operating it for many years. What happens is that in a lab run by a pathologist, we simply take over that lab entirely and bring in all the systems, processes, people, et cetera, from Metropolis. This is a model we've been running for a few years, and whenever we get the right opportunity, we just keep exploring it. What happens over a period of time after this is that some of these cases we look at acquiring them, or in some places we continue doing the model for a longer duration of time. This is something that is already in working.
Is that something you can do — could you give us the count of labs in this model?
I’ll need to get back to you with the precise figure, since it’s distributed across the markets and this has been running for roughly 10-odd years now. I’ll have to follow up with you specifically on the exact numbers for this.
Appreciate it. That's useful. I'll rejoin the queue.
The following question is from Surya Patra of PhillipCapital India. Go ahead, please.
Yes. Thank you for the chance to speak, ma'am. The first item concerns TruHealth, and it is clearly turning in a steady performance — a strong one at that. As you noted recently, radiology has also been folded in, and that is helping sustain the momentum there as well. Now, I believe you have launched a new initiative involving TruHealth Mind & Body. Could you share some details on it? What is the aim, and what in practical terms are we seeking to accomplish with this new initiative, and what growth might we be able to achieve from it?
TruHealth essentially consists of two components. One component involves essentially attempting to check what's happening in the body and mind, roughly from start to finish. In certain cases, these are consumers who come in saying, "Look, I haven't fallen sick, but I just want to find out what's going on." In certain cases, these are consumers who are coming in for some illness test, but are choosing to up-sell themselves to a bigger bundle and say that, "Look, if I am going to get pricked, then I might as well do more tests at one time." It's a combination of these two. Metropolis's attempt is to be a health partner to our consumers. To say that, "Look, any kind of information that you need for your body, whether it's coming through blood or whether it's coming through vitals or it's coming through basic radiology or a test for your cognitive assessment or your mental health, we are here to sort of provide it for you." It's just an attempt to make sure that we are screening every aspect of ourselves. We don't really have any particular targets for individual packages or individual things, but overall as a TruHealth portfolio, we certainly believe that we'll keep innovating new products and new options and keep growing it in multiple markets.
Is it a combination of even genomic and advanced radiology, ma'am?
Radiology — yes, that's right. Basic radiology, yes. Items such as X-ray, ECG, and sonography can occasionally be included. Genomics, though, isn't part of it so far. That could be something we do later, once we're more comfortable with the science behind predictive genomics, which at this point we believe is more useful and scientifically sound for illness. Predictive genomics for wellness has still not been validated in India.
Alright. The next question concerns the CGHS price revision — what took place there. My understanding is that the industry has begun to see the benefit. Hello, can you hear me?
Yeah, we can hear you fine. Please go ahead.
Yeah. About that CGHS pricing advantage that competitors are getting. Sure, if you're able to speak to it, fine — what share of our business does CGHS represent, and have we realized any gain from it?
Our CGHS contribution to the overall business was roughly around a percentage or so, right?
Oh, okay.
So we aren't seeing a big lift from the CGHS price increase, depending on how things play out. Whatever you can get out of that small business of ours, we definitely get it. In our situation, unlike some of the other peer group companies, the numbers are very low.
Alright.
Across the nation, we keep bringing hospitals into the CGHS panel. Clearly, that one-time benefit won't be there next year, but on the whole, we think this is a business that can keep expanding quickly as we continue to add more institutions to the panel.
Okay. In your opening remarks, you referenced your five strategies for growth. Just looking at it—since we're already seeing integration benefits come through—growth may therefore show some moderation in the current financial year for the organic business now. Is it fair to think that, as you alluded to, the focus is on B2B growth, extending into Tier 3-type areas, and that this is the core area beyond the qualitative or AI-related initiatives we're undertaking? What would the real driver be going forward?
To make that clear, and then Suren can discuss the plans. To make it clear, the figures we have now for Q1 represent organic growth. So we think, as we stated, that the guidance we consider achievable for the year is roughly 14%-15% for the year. Clearly, we mentioned that we anticipate margin expansion of 120 basis points-150 basis points this year, and that will come from plenty of productivity and operating leverage.
To give a bit more detail on this: we still hold to our medium-term CAGR guidance of roughly 14%-15%. Within that 14%-15%, around 9%-10% comes from growth in patient volumes, while the rest comes from product mix. That volume growth will in fact materialize thanks to two initiatives. The first is, naturally, our push into Tier 2 and Tier 3 towns along with the larger network we're building. Each quarter we now add somewhere between 200 and 250 new centers, and across two to three quarters those mature and start delivering the numbers. That cycle has in fact been running for five to six quarters at this point. It keeps giving us the benefits now. Patient volume growth will come from that. In parallel, at all our existing centers, plenty of on-the-ground initiatives, digital, and doctor engagement also help us drive patient volume growth from those existing centers. Their productivity rises. That's what gives me the patient volume growth, and that's why we're saying roughly 9%-10% is definitely achievable going forward. The mix is in fact improving, because we already discussed TruHealth and Specialty, and those now growing at about 17% for Specialty and 20% for TruHealth deliver realization benefits of roughly 5%-6%.
That's pretty much the broad growth strategy and how we see things shaping up going forward.
Thank you. Participants, to respect everyone's time and ensure fairness, please limit yourselves to 2 questions. Should you have additional questions, you're welcome to rejoin the queue. Our next question is from Sudarshan Agarwal at Axis Capital. Please go ahead.
A question I had concerns your center closures. You mentioned roughly 300 centers were added, yet the overall count of centers has actually declined. My assumption is that you've rationalized a portion of them. These would sit in Tier 2 and Tier 3 towns and be underperforming, so how should we view this going forward? On net additions, are you saying 500 will be added, or will attrition keep occurring?
Right. So, just about annually—roughly every 12 to 18 months—we go through a review of centers that aren't producing much and locations where quality problems exist, and so on. We simply work at shutting those down. Naturally, in certain instances the partner has also chosen to pursue something different, relocate away from the city, leave the country, or take a different direction in life. It's an ongoing routine. Each year we make a determination regarding how many of them truly haven't been productive for us and aren't deserving of our investment of effort and energy. That's the reason we close them out. On this occasion, we did the closing after close to 2 years—we shut down those 300 centers. The figure we're referring to, the 500-center expansion, is a net figure.
Understood. For my second question, regarding the Tier 2 and Tier 3 expansion you mentioned, what kind of traction are you seeing on the wellness side there? Your wellness portfolio, I'd imagine, sits more in your metro cities or core markets, correct? Is traction also solid in Tier 2 and Tier 3 markets? Given your push into Tier 2 and Tier 3, do you expect that wellness share to keep inching up over the next couple of years?
Right now, most of the wellness business, or TruHealth, is concentrated in the large cities — Tier 1 and to some extent Tier 2 towns. In the second part of Tier 2 towns, along with Tier 3 and beyond, TruHealth has begun picking up momentum. That is the reason we remain confident that an opportunity exists and there is headroom to grow the TruHealth portfolio further. Whenever a new center or a new town is added, the routine and semi-specialty services come first, then specialty follows, and TruHealth arrives after that. That is the order in which wellness gets built up. At present, we have plenty of opportunity to expand the TruHealth portfolio across Tier 1 and Tier 2 towns, and we are actively working on it.
Understood — I have additional questions, so I'll follow up on that front. Thanks.
Yes. Thanks.
Our following question is from Samit Basak of Kotak Institutional Equities. Go ahead, please.
Yeah, regarding that 5%-6% realization growth we saw this quarter, was it driven completely by TruHealth and specialty in exchange? Because when I look at revenue growth and contribution year over year, revenue growth was pretty much in line with the company's top line growth, and contribution was also roughly flat. I just wanted to understand whether any price hikes were part of that.
No — there's absolutely zero price increase this quarter. As a matter of fact, the most recent time we raised prices was January 2025. Nothing has gone up since then. We only mentioned the CGHS price hike, and that's a really tiny piece of our business. It honestly didn't do much for us. The bulk of it comes from organic growth, on both the volume side and the realization side. As you said, the realization growth was driven by TruHealth and Specialty, which grew 21% and 17% respectively.
How are we thinking about price increases over the near to medium term? Do you have any in the works?
Looking ahead, we aren't considering any price hike right now. When the right moment comes and the market can bear a bit more on pricing, we would certainly want to move on that. To be sure, the plan is at minimum to hand over to consumers, at the proper time, some portion of whatever inflation reaches us.
My second question concerns the 27%-28% medium-term margin guidance for the next couple of years. On one side, we're seeing better productivity at a number of our mature collection centers and labs. On the other side, we're also moving into Tier 2 and Tier 3 towns, where the margin profile is somewhat lower. And with the geopolitical situation going on right now, there's RM pressure as well. Could you break down that margin guidance — perhaps how much of a drag we'd face from these cost pressures and worsening geodynamics, and how much benefit would come from the productivity gains?
Look, at this point we aren't pushing out past those 750 towns any further. What we're doing is going deeper within the 750 towns. We've got our network, our logistics system, and our collection center in place. We're going deeper into those 750 towns. We're not opening up beyond 750 towns and adding more cost right now. Second, we've also stopped the lab expansion plan that we'd been running for almost the last five quarters. We haven't really carried on with expanding the labs. Those two things will ensure we don't face any further margin stress from new towns and new labs. Right? Boosting productivity from the existing centers, along with the new centers coming up, will stay on the agenda, and that's where we have confidence in getting our margins to 27% and 28%, supported by operating leverage and some of the other cost initiatives we've already put in place.
To build on that point, the economics in Tier 2 and Tier 3 cities are not worse than in the metros. Moving into smaller markets doesn't imply that the margin profile gets worse. In fact, we've observed the margin profile to be quite strong in strong branded markets, so we aren't concerned that those economics will shift significantly.
Alright, thanks.
Shyam Srinivasan from Goldman Sachs has the next question — go ahead, please.
Yes. Good morning, and thanks for letting me ask. My first question concerns B2B revenues. After roughly 15% organic growth last year, we held that level — sorry, 15% in quarter four — and in quarter one we've more or less kept the same pace. I also appreciate the breakdown showing volume at 6%. What I'd like to understand is the 9%: how should we view it — is it TruHealth plus Specialty growing more quickly, and is that what's driving higher realizations? If you could explain the dynamics around B2B and perhaps add a note on competitive intensity as well, please.
Let me give you an update on that figure. In quarter four, when we mentioned 15% B2B growth, that was mostly organic. The newly acquired entities, such as Core and others, were not included in the denominator. This time, when we state 15% B2B business growth, Core revenue is included in the denominator as well. Right? That is, at least number-wise, one point of clarification I want to offer. The majority of our B2B business is in specialty. Because, ultimately, who is our B2B customer? B2B customers are smaller labs, hospitals, and of course, institutional business, et cetera. We are getting more and more specialty from B2B hospitals and B2B labs. Of course, our corporate and other institutional business—that is the only area where we have anything beyond the specialty business. Largely, you should assume it is specialty business.
When it comes to competitive dynamics, as Suren mentioned, your customers are the B2B labs, though it really hinges on the type of lab you go out and bring on, correct? Take the country as a whole: there are roughly three lakh labs, and merely about 10% of those are operated by MD pathologists. Technicians run 90%. So what ends up happening is that the tests they can perform in-house versus the tests they can refer out differ, since the referring doctor is not the same. Typically, it's the GP referring to the technician lab, and so they're treating more common illnesses, which might or might not call for specialized tests. As a result, the technician lab will handle a handful of routine tests on its own and send out what we term a semi-specialized test. The MD pathologist labs, along with hospitals and nursing homes, are the ones that traditionally have specialists attached to them, and those specialists then treat more complex diseases; hence, although hospitals and MD labs perform routine tests in-house, they send out more specialty tests. Much of this comes down to choosing which kind of customer you want business from, and so Metropolis targets those customers who genuinely can outsource specialized tests, and we in fact assist them in growing by building that market for them too.
When it comes to the competitive dynamics, we haven't observed anything irrational taking place. What I mean is that the usual level of competition in diagnostics, which we've been seeing for 10 to 15 years, is still present, and obviously everyone is fighting for their share of the pie. That said, we've clearly seen that not everyone is succeeding in the same manner. In our industry, it's easy to collect samples and simply build distribution. What truly sets one player apart from another is the unit economics of those samples and the quality of that business. Typically, we've observed that many of the new entrants who've arrived are chasing volume with high servicing costs, and as a result, they aren't able to make money in this industry. Most of them can reach INR 50 crore, INR 75 crore a year by operating this way, and then they come to realize they aren't making money. They come to understand that this business is actually a bit harder than they initially believed. Perhaps they begin to stagnate somewhat. Scaling profitably is truly the challenge and the objective in this business for everyone. Not all people are able to accomplish it unless you possess the right domain and the right scale opportunities and the capacity to build trust with doctors, which brings you a full price patient walking in, along with specialty tests.
Thanks. Our following question is from Abin Benny at JM Financial Institutional Securities. Please proceed.
Thanks for giving me the chance to ask. I hope you can hear me clearly. My first question is this: if we think about the next round of possible acquisitions, say down the road, which new geographies and capabilities would we want to concentrate on, and are there any white spaces we might be looking to fill?
We still see plenty of markets throughout every region of India where our consumer brand may not be strong in a given sector or market. Our stance would remain open toward bolt-on acquisitions, following the same approach we've taken before: buying a solid consumer brand built on ethical practices, strong science, and healthy unit economics. The people involved matter too, since they stay on working with you, so a good reputation counts, and all of it needs to come at a disciplined valuation. That mix isn't always simple to locate, but we keep looking for such deals. We're likewise open to bigger transactions if, in the end, there's value creation for our shareholders, meaning it's EPS accretive, and we can secure the right prices and potentially turn things around.
Understood. On your second question: in pharma, the GLP-1 trend is now declining. What sort of trend are you seeing on the diagnostics side, and could you give any color on how the industry is currently shaping up for us?
Are you asking about something specific to GLP-1?
Yes, ma'am. The GLP-1 and diabetic sector.
The tests needed for pre-screening or pre-prescription of a GLP-1 are pretty standard tests. We've put together packages for pre-GLP-1 testing, but doctors may be writing their own prescriptions and not necessarily only writing the packages. A number of these tests are fairly common for other diseases or illnesses or areas as well. It's quite hard to sort of separate out whether it is meant for GLP-1 or not. That could be a contributor to the growth as well, in the organic growth it's possible, and not be sort of specified under GLP-1 itself. I think it's still early days because while people are taking injections and drugs as we've seen, I think this will play out a little longer over time.
Understood, ma'am. Thanks so much.
Our following question is from Kunal Thanvi at Banyan Tree Advisors. Kindly proceed.
Hi, thanks for the chance to ask. I had a couple of questions. The first one is for Ameera — you mentioned three reasons why growth has sped up for us and for the industry, and one of them was that organized players keep gaining more share. Could you shed more light on that? What trends are you seeing? Has there been any unusual increase over the last 18 months or so, or is it just the usual slow share gain that we've been achieving? My second question: when we look at our growth and at all the national players, the bigger ones, we've seen base rate growth tick up for every large player, Metropolis included. Of course, that has been a bit above the guidance you stated for this year. Any thoughts on the guidance? When we say 14%-15%, are we being conservative, or do you feel this quarter's growth was somewhat one-off and that from 2Q it will return to the base rate for us and for the industry? Because this is now three quarters in a row where, apart from Metropolis, other players have also been inching up on their base rate growths.
There are two questions here. Thank you.
On your first question, look, there’s no third-party industry-level data I can give you on the shift from unorganized to organized. I don’t have any data points. All I can say is anecdotal: when we talk with vendors in the industry and get their assessment of the services they provide to the smaller unorganized sector — products and services — versus what they provide to the larger players, the anecdotal data we get from them is that volume growth at the smaller labs and in the unorganized sector is slower. They’re buying fewer materials from them, and it’s faster at some of the organized players. That’s one piece of anecdotal evidence you get. The same thing happens when we engage with our B2B customers on the ground. You get a sense that a price increase is difficult for them and volume increase is marginal. So you also find very small ones shutting down. You can definitely see some green shoots or early trends of organization in the industry. It’s at a slow and steady pace. There’s no catalyst causing it to now transform from a 10%-15% organized industry to suddenly a 30% — such that you’d see a very marked change.
My view is that each year, as has been happening, we'll keep watching this process grind down and consolidate, though the path is slower. It won't be an especially quick path. I think regarding your.
The second question concerns your forecast for the—
On the guidance front — look, I don't think anybody here can see the future. The truth is that climate change is altering everything for everyone. Weather patterns are unpredictable, and weather has a big effect on our business. Those conditions then have an impact and give rise to diseases, which in turn call for testing. That's pretty hard to forecast. I think we'd prefer to stay with the guidance of 14%-15%, since, as you've seen in the two quarters prior to this one, we've managed to hit that figure. We really don't want to fixate on quarter-by-quarter seasonality, because predicting life that way is extremely difficult. I think across the full year, we feel reasonably comfortable about reaching a 14%-15% number.
Absolutely.
Much appreciated. Our following question is from Tarun Bhatnagar at Tribeca Investment Partners. The line is yours now.
Hello, and thanks for taking my question. It concerns pricing. One of your big competitors said they're taking another look at pricing. What I'd like to know is whether you believe the industry is more open now to raising prices, and which factors would decide whether you do raise a price? My second question is whether you can give us guidance on CapEx for the coming few years. Thank you.
Metropolis, over the past two to three years, you've seen us raise prices each year — the last three years, if you look at it. This is a year in which we haven't done a price increase. That's mainly due to the GST benefits that have come into the industry, and we felt passing them on to the consumer is the right thing to do. That's why we haven't raised prices. Otherwise, there's always cost inflation, and we'd like to factor that into a price increase. This year, then, we didn't do it for the reasons I mentioned. Going forward, of course, part of the inflation will have to be passed on to the consumer. Wherever that needs to be done, we will definitely do it. As far as CapEx is concerned, I think last year we did INR 65 crore of CapEx last year, and I think our CapEx requirement for this year will also be along similar lines. I'm saying for the group, including all the acquired entities, everything put together.
Thanks.
Yeah.
Our following question is from Anshul Agrawal of Emkay Global Financial Services. Anshul, go ahead.
Hey, thanks for letting me ask. My first question is about the network. Has your network rationalization planning wrapped up? And will you be rationalizing additional centers down the road?
No, Anshul, I believe I mentioned this to you already — we only go through this exercise every 18 months or 24 months, and only when there are centers that aren't productive or aren't meeting the quality standards we require. Of course, that's also the case if some partners decide to leave, and so on. Please also keep in mind that this rationalization was carried out without any impact on revenues, since there's barely any revenue generated by these centers, which post very low productivity numbers. This won't be happening each quarter. It might only take place once every 12 to 18 months.
Understood, sir — that’s very clear. I just want to make sure I follow the math behind the target you provided of 30 centers servicing one lab by the end of the year: if I simply add roughly, say, 500 net additions or gross additions going forward, the lab network kind of shrinks. Is some rationalization also expected to take place within the lab network?
If you look at it, our lab numbers over the past two quarters have only been declining, right? When we acquired Core, we also shut down all the Core labs wherever we had overlapping facilities. I think by and large there's no more room for us to rationalize the labs as such. The ratio will rise mainly because of the centers we'll be adding. If we add another 500 centers this year on a net basis, that will push the ratio up by another five per lab. That's why it's getting closer to that 30 number.
Understood, sir. That's all from me. Many thanks.
Raman Kerti from Sequent Investments has the next question. The line is yours.
Hi there, sir. Are you able to hear me?
Yeah.
Apologies if I'm asking something you've already covered — I hopped on the call a bit late. Could you clarify what CGHS contributed in revenue for the quarter?
As I've said before, for us the CGHS accounts for roughly a percentage of overall revenue. That isn't a large figure.
Got it. Sir, one more thing on Core Diagnostics and TruHealth — I'd just like to get a sense of how average revenue per test for the Core Diagnostics and TruHealth portfolio compares with Metropolis, and at full utilization, what the margin gap is between the two of them? And when we compare the Core and TruHealth portfolio against the standalone Metropolis portfolio, what will the incremental margin difference be?
Core is a completely separate unit. TruHealth is what we'd call a business vertical for us — just to clarify that. At TruHealth, our ticket size right now is roughly INR 2,500, that's the ticket size. Margins there are largely consistent with the company's lines of margins. That's how it is. Core Diagnostics sits overall within our B2B segment. The B2B revenue per patient we discussed — that's the revenue per patient from Core Diagnostics as well. On Core Diagnostics margins, we already mentioned this last quarter, and in this quarter we're at a high-single digit margin from the Core Diagnostics business.
Is it fair to think that once Core Diagnostics is fully integrated and has gained traction—say, roughly 1 or 2 years down the road—both Core and TruHealth will post margins better than your typical 22%-24%? Would their margin profiles look alike? From a margin standpoint, I'm just trying to get a sense of how much additional margin separates a standard test portfolio from a comprehensive specialized one at that stage.
Let me jump in here for a moment. Honestly, whatever data I hand over won't really address what you're asking, since the matter isn't that straightforward. This isn't a product where you can claim that a comprehensive testing portfolio carries a particular margin and such. Within a comprehensive testing portfolio, there are also lots of different tests, each with its own distinct margins. What matters is how the tests in that portfolio are combined. At a high level, we noted that at the time of the Core acquisition, we had stated our intention to lift the Core margin to 25% within 3 to 4 years of completing that acquisition. That is the direction we're heading. To illustrate, at the close of the first year, in the last quarter, we observed a margin of roughly 8% for Core. This year, that will clearly climb further in that direction. As we said, it will take us 3 to 4 years to reach that figure. As Suren mentioned, the TruHealth portfolio already sits at the company's margin level. So both will stay aligned and will be accretive to our EBITDA growth in the next phase.
Thanks. That brings us to the end of the Q&A for today, everyone. At this point, I'd like to pass things back to management for some closing remarks.
Thanks, everyone, for being on this Q1 FY 2027 call today. As our remarks made clear, the management team stays very optimistic about what lies ahead in FY 2026 to 2027 for Metropolis. Our view is that every lever is available to us — not just for solid growth this year, but also for the margin expansion strategy. Our three-year strategies are in place and genuinely keep pushing the business forward organically in a very positive way. Obviously, we keep scouting for the right deals with the right people — not simply to add revenue or to do deals for their own sake, but for the right strategic direction. Those will keep sitting on top of everything we do organically. Structural trends in the industry keep pointing in a positive direction. We're all looking forward to a great Q2, just as we had a really good Q1. Thanks to all of you for joining us, and we'll chat with you next quarter.
Appreciate it, ma'am. Everyone, that brings this conference call to a close on behalf of JM Financial Institutional Securities. Thanks for being with us — you can go ahead and disconnect your lines now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Metropolis Healthcare Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Metropolis Healthcare Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.